Inscripta hires Jason Gammack as first chief commercial officer

Inscripta hires Jason Gammack as first chief commercial officer

BOULDER -- Gene-editing technology company Inscripta today announced the hiring of Jason T. Gammac kas the company's first chief commercial officer. Gammack, a 25-year veteran of life... Read More

Friday November 2, 2018 0 comments Tags: Boulder, Inscripta, Jason Gammack, Kevin Ness

Inscripta announces strategic acquisition of Solana Biosciences

Inscripta announces strategic acquisition of Solana Biosciences

BOULDER -- Inscripta , a leading gene-editing technology company, today announced the strategic acquisition of Solana Biosciences, a life sciences company founded by Illumina (NASDAQ: ILMN)... Read More

Thursday September 6, 2018 0 comments Tags: Boulder, Inscripta, Solana Biosciences, Dr. Kevin Ness, Tom Rosso, John Stuelpnagel

Inscripta announces two major milestones

Inscripta announces two major milestones

BOULDER -- Inscripta , a gene-editing technology company, announced two significant milestones. First, the USPTO granted Inscripta its first patent covering systems using MAD7, the... Read More

Friday July 13, 2018 0 comments Tags: Boulder, Inscripta, Dr. Kevin Ness, Jon Moore, MAD7, MAD2

Inscripta raises $55.5M to advance gene-editing tech

Inscripta raises $55.5M to advance gene-editing tech

BOULDER -- Inscripta , a leading gene-editing technology company, announced it closed a $55.5 million Series C funding round led by Merieux Developpement and Paladin Capital Group. ... Read More

Wednesday February 28, 2018 0 comments Tags: Boulder, Inscripta, Dr. Kevin Ness, gene editing